- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01142947
Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-Ethnicity (SAPPHIRE) (SAPPHIRE)
March 11, 2019 updated by: keoki williams, Henry Ford Health System
Inhaled corticosteroids (ICS) are considered first-line treatment for persistent asthma, yet little is known about the genetic factors that influence response to this therapy.
This study seeks to quantify response to ICS therapy in African American and white patients, as well as look for genetic markers that predict treatment response.
Study Overview
Detailed Description
Inhaled corticosteroids (ICS) are considered first-line therapy for the management and control of patients with persistent asthma.
Use of inhaled steroids has been associated with improved lung function, diminished symptoms, and fewer exacerbations.
However studies show considerable inter-subject variability in ICS response.
It has also been estimated that corticosteroid resistance accounts for half of all asthma-related health care costs.
Therefore, identifying factors associated with ICS response is both clinical and economically important.
African-American patients have been understudied with respect to genetic predictors of asthma controller medication response, and to date there have been no sufficiently powered genome-wide association studies of ICS treatment response among African American individuals with asthma.
This issue is of particular importance, since African-American individuals are disproportionately affected by asthma-related complications.
In this proposal, we seek to identify novel genetic loci associated with ICS treatment responsiveness (defined by the change in Asthma Control Test score) among African American individuals treated with beclomethasone dipropionate (BD) for 6 weeks.
We will attempt to validate loci identified in the discovery set by 1) reassessing these variants for their interaction with ICS treatment on asthma exacerbations in a separate group of African American individuals with asthma, and 2) by reexamining the genetic association with change in asthma control among similarly treated (i.e., treatment with 6 weeks of BD) European Americans with asthma.
Study Type
Interventional
Enrollment (Actual)
362
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Henry Ford Health System
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
12 years to 56 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria for Discovery Group:
- Age 12-56 years
- Physician diagnosis of asthma (identified by using encounter data prior to screening and by the survey administered at the clinic visit)
- Bronchodilator reversibility on pulmonary function testing (i.e., improvement in baseline FEV1 of >12%)
- African-American/Black self-reported race-ethnicity
Exclusion Criteria for Discovery Group:
- Smoking in the preceding year or <10 pack-year smoking history total
- Pregnant at the time of enrollment or intending to get pregnant during the 6-week treatment period
- Oral or inhaled corticosteroid use in the 4 weeks preceding enrollment
- Prior diagnosis of chronic obstructive pulmonary disease or emphysema
- Prior diagnosis of congestive heart failure
- Self-reported race not African-American/Black or Hispanic ethnicity (these groups could be included in Replication/Validation group)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: beclomethasone dipropionate (BD)
Patients who meet eligibility criteria will be treated with 6 weeks of beclomethasone dipropionate to assess change in pulmonary function and asthma control.
These change will be used as phenotypes in a genetic association study.
There is no placebo group.
|
160 mcg twice a day (320 mcg per day total)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Asthma Control Test Score
Time Frame: 6 weeks
|
Patients will be treated with 6 weeks of inhaled beclomethasone diproprionate (BD) treatment and the change in Asthma Control Test (ACT) quantified.
The composite ACT score measured at each time point ranged from 5-25 (with higher scores reflective of better asthma control).
Therefore, the absolute change in ACT score from before to after treatment could range from -20 to +20.
|
6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: L. Keoki Williams, MD, MPH, Henry Ford Health System
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2007
Primary Completion (Actual)
February 1, 2017
Study Completion (Actual)
March 11, 2019
Study Registration Dates
First Submitted
June 11, 2010
First Submitted That Met QC Criteria
June 11, 2010
First Posted (Estimate)
June 14, 2010
Study Record Updates
Last Update Posted (Actual)
April 2, 2019
Last Update Submitted That Met QC Criteria
March 11, 2019
Last Verified
March 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Immune System Diseases
- Lung Diseases
- Hypersensitivity, Immediate
- Bronchial Diseases
- Lung Diseases, Obstructive
- Respiratory Hypersensitivity
- Hypersensitivity
- Asthma
- Physiological Effects of Drugs
- Anti-Inflammatory Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Anti-Asthmatic Agents
- Respiratory System Agents
- Beclomethasone
Other Study ID Numbers
- AI079139
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
Johann Wolfgang Goethe University HospitalCompleted
-
Parc de Salut MarRecruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Universita di VeronaCompleted
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
-
Johann Wolfgang Goethe University HospitalCompletedExercise-induced AsthmaGermany
Clinical Trials on beclomethasone dipropionate
-
SOFAR S.p.A.Completed
-
Teva Branded Pharmaceutical Products R&D, Inc.Completed
-
Adamis Pharmaceuticals CorporationWithdrawn
-
Adamis Pharmaceuticals CorporationWithdrawn
-
Research in Real-Life LtdTeva Branded Pharmaceutical Products R&D, Inc.Completed
-
SoligenixNational Cancer Institute (NCI)Completed
-
Casa Sollievo della Sofferenza IRCCSFondazione SchenaUnknownUlcerative Colitis Chronic MildItaly
-
Research in Real-Life LtdTeva Branded Pharmaceutical Products R&D, Inc.Completed
-
Roswell Park Cancer InstituteCompletedGraft Versus Host DiseaseUnited States
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedAsthmaUnited States, Puerto Rico